Visit the Website for Patients 
Français
Subscribe to our newsletter!
Follow the latest news from CATALIS and Clinical Trials Quebec
Approval Performances
KRAScendo 1 (BO45217)
Non-Small Cell Lung Cancer (NSCLC) Phase III
- 9.6 weeks
- 2nd site activated in Canada
MARITIME-CV-20220196
ASCVD and Obesity Phase III
- 3.8 weeks
MARITIME-CV-20220196
ASCVD and Obesity Phase III
- 8 weeks
MARITIME-CV-20220196
ASCVD and Obesity Phase III
- 8.4 weeks
MARITIME-CV-20220196
ASCVD and Obesity Phase III
- 11.8 weeks
MARITIME-CV-20220196
ASCVD and Obesity Phase III
- 15 weeks
MARITIME-HF-20230227
Obesity and Heart Failure Phase III
- 12 weeks
NETTER-3 (CAAA601A62301)
Oncology: GEP-NET Phase III
- 8 weeks
- 2nd site activated worldwide
panSOHO
HER2 Solid Tumors Phase II
- 10.8 weeks
- 1st site activated in Canada
PDY18663
Graves' disease Phase II
- 7.2 weeks
PRESTO
Pulmonary Disease Phase IIb
- 5.2 weeks
PRESTO
Pulmonary Disease Phase IIb
- 8 weeks
SERENIA
Sepsis-associated acute Kidney Injury Phase II
- 9.8 weeks
- 2nd site activated worldwide and 1st site activated in Canada
SERENIA
Sepsis-associated acute Kidney Injury Phase II
- 9 weeks
SERENIA
Sepsis-associated acute Kidney Injury Phase II
- 11.8 weeks
WO45654
Breast Cancer Phase III
- 9.2 weeks
- 1st site activated in Canada
WO45654
Breast Cancer Phase III
- 9 weeks
WO45654
Breast Cancer Phase III
- 11 weeks
WO45654
Breast Cancer Phase III
- 17.4 weeks
WO45654 (Inavo123)
Breast Cancer Phase III
- 8.2 weeks
- 1st site activated in Canada
WO45654 (Inavo123)
Breast Cancer Phase III
- 9 weeks
WO45654 (Inavo123)
Breast Cancer Phase III
- 11 weeks
WP45335
Hematology – Von Willebrand Disease Phase Non-Interventional
- 15.2 weeks
WP45338
Hematology - Von Willebrand Disease Phase III
- 13.6 weeks
- 1st site activated in Canada